nodes	percent_of_prediction	percent_of_DWPC	metapath
Nevirapine—CYP2A6—esophageal cancer	0.711	1	CbGaD
Nevirapine—CYP2C9—Capecitabine—esophageal cancer	0.0407	0.407	CbGbCtD
Nevirapine—CYP2B6—Cisplatin—esophageal cancer	0.0388	0.388	CbGbCtD
Nevirapine—CYP2C9—Cisplatin—esophageal cancer	0.0205	0.205	CbGbCtD
Nevirapine—Hepatitis acute—Methotrexate—esophageal cancer	0.00377	0.0491	CcSEcCtD
Nevirapine—Congenital anomaly—Capecitabine—esophageal cancer	0.00193	0.0252	CcSEcCtD
Nevirapine—Developmental delay—Capecitabine—esophageal cancer	0.00193	0.0252	CcSEcCtD
Nevirapine—Hepatitis cholestatic—Capecitabine—esophageal cancer	0.00183	0.0237	CcSEcCtD
Nevirapine—Opportunistic infection—Methotrexate—esophageal cancer	0.00136	0.0177	CcSEcCtD
Nevirapine—Hepatotoxicity—Cisplatin—esophageal cancer	0.00129	0.0168	CcSEcCtD
Nevirapine—Hypertriglyceridaemia—Capecitabine—esophageal cancer	0.00128	0.0166	CcSEcCtD
Nevirapine—Necrosis—Cisplatin—esophageal cancer	0.00127	0.0165	CcSEcCtD
Nevirapine—Ulcerative stomatitis—Methotrexate—esophageal cancer	0.00119	0.0154	CcSEcCtD
Nevirapine—Liver injury—Cisplatin—esophageal cancer	0.00119	0.0154	CcSEcCtD
Nevirapine—Blood triglycerides increased—Capecitabine—esophageal cancer	0.00112	0.0146	CcSEcCtD
Nevirapine—Ulcer—Cisplatin—esophageal cancer	0.00105	0.0137	CcSEcCtD
Nevirapine—Pain—Carboplatin—esophageal cancer	0.00104	0.0135	CcSEcCtD
Nevirapine—Blister—Capecitabine—esophageal cancer	0.00102	0.0133	CcSEcCtD
Nevirapine—Hepatocellular injury—Cisplatin—esophageal cancer	0.000998	0.013	CcSEcCtD
Nevirapine—Rash erythematous—Capecitabine—esophageal cancer	0.00096	0.0125	CcSEcCtD
Nevirapine—Body temperature increased—Carboplatin—esophageal cancer	0.000959	0.0125	CcSEcCtD
Nevirapine—Skin exfoliation—Cisplatin—esophageal cancer	0.000952	0.0124	CcSEcCtD
Nevirapine—Hepatotoxicity—Capecitabine—esophageal cancer	0.000952	0.0124	CcSEcCtD
Nevirapine—Liver disorder—Methotrexate—esophageal cancer	0.000803	0.0104	CcSEcCtD
Nevirapine—Ulcer—Capecitabine—esophageal cancer	0.000777	0.0101	CcSEcCtD
Nevirapine—Inflammation—Capecitabine—esophageal cancer	0.000758	0.00986	CcSEcCtD
Nevirapine—Blood pressure increased—Capecitabine—esophageal cancer	0.000735	0.00956	CcSEcCtD
Nevirapine—Hepatotoxicity—Methotrexate—esophageal cancer	0.000709	0.00922	CcSEcCtD
Nevirapine—Skin exfoliation—Capecitabine—esophageal cancer	0.000702	0.00913	CcSEcCtD
Nevirapine—Face oedema—Cisplatin—esophageal cancer	0.000699	0.00909	CcSEcCtD
Nevirapine—Necrosis—Methotrexate—esophageal cancer	0.000697	0.00907	CcSEcCtD
Nevirapine—Mouth ulceration—Capecitabine—esophageal cancer	0.000665	0.00865	CcSEcCtD
Nevirapine—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000652	0.00848	CcSEcCtD
Nevirapine—Pancreatitis—Cisplatin—esophageal cancer	0.000614	0.00798	CcSEcCtD
Nevirapine—Bone disorder—Methotrexate—esophageal cancer	0.000606	0.00788	CcSEcCtD
Nevirapine—Hepatic failure—Capecitabine—esophageal cancer	0.000594	0.00772	CcSEcCtD
Nevirapine—Ulcer—Methotrexate—esophageal cancer	0.000579	0.00753	CcSEcCtD
Nevirapine—Hepatic enzyme increased—Methotrexate—esophageal cancer	0.000579	0.00753	CcSEcCtD
Nevirapine—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.000566	0.00736	CcSEcCtD
Nevirapine—Inflammation—Methotrexate—esophageal cancer	0.000564	0.00734	CcSEcCtD
Nevirapine—Dermatitis bullous—Capecitabine—esophageal cancer	0.000558	0.00726	CcSEcCtD
Nevirapine—Renal failure—Cisplatin—esophageal cancer	0.000548	0.00713	CcSEcCtD
Nevirapine—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000547	0.00711	CcSEcCtD
Nevirapine—Conjunctivitis—Cisplatin—esophageal cancer	0.000542	0.00705	CcSEcCtD
Nevirapine—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000528	0.00686	CcSEcCtD
Nevirapine—Skin exfoliation—Methotrexate—esophageal cancer	0.000523	0.0068	CcSEcCtD
Nevirapine—Face oedema—Capecitabine—esophageal cancer	0.000515	0.0067	CcSEcCtD
Nevirapine—Mouth ulceration—Methotrexate—esophageal cancer	0.000495	0.00644	CcSEcCtD
Nevirapine—Liver function test abnormal—Capecitabine—esophageal cancer	0.000493	0.00641	CcSEcCtD
Nevirapine—Connective tissue disorder—Cisplatin—esophageal cancer	0.000492	0.0064	CcSEcCtD
Nevirapine—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000481	0.00625	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000481	0.00625	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000471	0.00612	CcSEcCtD
Nevirapine—Lymphadenopathy—Methotrexate—esophageal cancer	0.000466	0.00606	CcSEcCtD
Nevirapine—Immune system disorder—Cisplatin—esophageal cancer	0.000452	0.00588	CcSEcCtD
Nevirapine—Hepatic failure—Methotrexate—esophageal cancer	0.000442	0.00575	CcSEcCtD
Nevirapine—Erythema—Cisplatin—esophageal cancer	0.000436	0.00567	CcSEcCtD
Nevirapine—Neutropenia—Capecitabine—esophageal cancer	0.000431	0.00561	CcSEcCtD
Nevirapine—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000421	0.00548	CcSEcCtD
Nevirapine—Hyperglycaemia—Capecitabine—esophageal cancer	0.000416	0.00541	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000408	0.0053	CcSEcCtD
Nevirapine—Ill-defined disorder—Cisplatin—esophageal cancer	0.000405	0.00526	CcSEcCtD
Nevirapine—Renal failure—Capecitabine—esophageal cancer	0.000404	0.00526	CcSEcCtD
Nevirapine—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000403	0.00524	CcSEcCtD
Nevirapine—Anaemia—Cisplatin—esophageal cancer	0.000403	0.00524	CcSEcCtD
Nevirapine—Jaundice—Capecitabine—esophageal cancer	0.000401	0.00521	CcSEcCtD
Nevirapine—Conjunctivitis—Capecitabine—esophageal cancer	0.0004	0.0052	CcSEcCtD
Nevirapine—Malaise—Cisplatin—esophageal cancer	0.000393	0.00511	CcSEcCtD
Nevirapine—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000389	0.00506	CcSEcCtD
Nevirapine—Agranulocytosis—Capecitabine—esophageal cancer	0.000384	0.00499	CcSEcCtD
Nevirapine—Myalgia—Cisplatin—esophageal cancer	0.000371	0.00483	CcSEcCtD
Nevirapine—Hepatitis—Capecitabine—esophageal cancer	0.000369	0.0048	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000369	0.00479	CcSEcCtD
Nevirapine—Liver function test abnormal—Methotrexate—esophageal cancer	0.000367	0.00477	CcSEcCtD
Nevirapine—Discomfort—Cisplatin—esophageal cancer	0.000367	0.00477	CcSEcCtD
Nevirapine—Connective tissue disorder—Capecitabine—esophageal cancer	0.000363	0.00472	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000358	0.00465	CcSEcCtD
Nevirapine—Anaphylactic shock—Cisplatin—esophageal cancer	0.000356	0.00463	CcSEcCtD
Nevirapine—Oedema—Cisplatin—esophageal cancer	0.000356	0.00463	CcSEcCtD
Nevirapine—Erythema multiforme—Capecitabine—esophageal cancer	0.000349	0.00454	CcSEcCtD
Nevirapine—Nervous system disorder—Cisplatin—esophageal cancer	0.000349	0.00454	CcSEcCtD
Nevirapine—Thrombocytopenia—Cisplatin—esophageal cancer	0.000348	0.00453	CcSEcCtD
Nevirapine—Skin disorder—Cisplatin—esophageal cancer	0.000346	0.0045	CcSEcCtD
Nevirapine—Eosinophilia—Methotrexate—esophageal cancer	0.00034	0.00442	CcSEcCtD
Nevirapine—Anorexia—Cisplatin—esophageal cancer	0.000339	0.00441	CcSEcCtD
Nevirapine—Pancreatitis—Methotrexate—esophageal cancer	0.000337	0.00438	CcSEcCtD
Nevirapine—Immune system disorder—Capecitabine—esophageal cancer	0.000334	0.00434	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000324	0.00422	CcSEcCtD
Nevirapine—Erythema—Capecitabine—esophageal cancer	0.000321	0.00418	CcSEcCtD
Nevirapine—Neutropenia—Methotrexate—esophageal cancer	0.000321	0.00418	CcSEcCtD
Nevirapine—Paraesthesia—Cisplatin—esophageal cancer	0.00032	0.00416	CcSEcCtD
Nevirapine—Decreased appetite—Cisplatin—esophageal cancer	0.000309	0.00402	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000307	0.004	CcSEcCtD
Nevirapine—Pain—Cisplatin—esophageal cancer	0.000304	0.00396	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000304	0.00395	CcSEcCtD
Nevirapine—Renal failure—Methotrexate—esophageal cancer	0.000301	0.00391	CcSEcCtD
Nevirapine—Ill-defined disorder—Capecitabine—esophageal cancer	0.000298	0.00388	CcSEcCtD
Nevirapine—Conjunctivitis—Methotrexate—esophageal cancer	0.000298	0.00387	CcSEcCtD
Nevirapine—Anaemia—Capecitabine—esophageal cancer	0.000297	0.00386	CcSEcCtD
Nevirapine—Feeling abnormal—Cisplatin—esophageal cancer	0.000293	0.00381	CcSEcCtD
Nevirapine—Malaise—Capecitabine—esophageal cancer	0.00029	0.00377	CcSEcCtD
Nevirapine—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00029	0.00377	CcSEcCtD
Nevirapine—Agranulocytosis—Methotrexate—esophageal cancer	0.000286	0.00372	CcSEcCtD
Nevirapine—Body temperature increased—Cisplatin—esophageal cancer	0.000281	0.00366	CcSEcCtD
Nevirapine—Hepatitis—Methotrexate—esophageal cancer	0.000275	0.00357	CcSEcCtD
Nevirapine—Arthralgia—Capecitabine—esophageal cancer	0.000274	0.00356	CcSEcCtD
Nevirapine—Myalgia—Capecitabine—esophageal cancer	0.000274	0.00356	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000272	0.00353	CcSEcCtD
Nevirapine—Discomfort—Capecitabine—esophageal cancer	0.00027	0.00352	CcSEcCtD
Nevirapine—Oedema—Capecitabine—esophageal cancer	0.000262	0.00341	CcSEcCtD
Nevirapine—Hypersensitivity—Cisplatin—esophageal cancer	0.000262	0.00341	CcSEcCtD
Nevirapine—Erythema multiforme—Methotrexate—esophageal cancer	0.00026	0.00338	CcSEcCtD
Nevirapine—Nervous system disorder—Capecitabine—esophageal cancer	0.000257	0.00335	CcSEcCtD
Nevirapine—Thrombocytopenia—Capecitabine—esophageal cancer	0.000257	0.00334	CcSEcCtD
Nevirapine—Asthenia—Cisplatin—esophageal cancer	0.000255	0.00332	CcSEcCtD
Nevirapine—Skin disorder—Capecitabine—esophageal cancer	0.000255	0.00331	CcSEcCtD
Nevirapine—Anorexia—Capecitabine—esophageal cancer	0.00025	0.00325	CcSEcCtD
Nevirapine—Immune system disorder—Methotrexate—esophageal cancer	0.000248	0.00323	CcSEcCtD
Nevirapine—Diarrhoea—Cisplatin—esophageal cancer	0.000243	0.00317	CcSEcCtD
Nevirapine—Erythema—Methotrexate—esophageal cancer	0.000239	0.00311	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000239	0.00311	CcSEcCtD
Nevirapine—Paraesthesia—Capecitabine—esophageal cancer	0.000236	0.00306	CcSEcCtD
Nevirapine—Decreased appetite—Capecitabine—esophageal cancer	0.000228	0.00297	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000226	0.00295	CcSEcCtD
Nevirapine—Vomiting—Cisplatin—esophageal cancer	0.000226	0.00294	CcSEcCtD
Nevirapine—Fatigue—Capecitabine—esophageal cancer	0.000226	0.00294	CcSEcCtD
Nevirapine—Rash—Cisplatin—esophageal cancer	0.000224	0.00292	CcSEcCtD
Nevirapine—Pain—Capecitabine—esophageal cancer	0.000224	0.00292	CcSEcCtD
Nevirapine—Dermatitis—Cisplatin—esophageal cancer	0.000224	0.00292	CcSEcCtD
Nevirapine—Ill-defined disorder—Methotrexate—esophageal cancer	0.000222	0.00289	CcSEcCtD
Nevirapine—Anaemia—Methotrexate—esophageal cancer	0.000221	0.00288	CcSEcCtD
Nevirapine—Feeling abnormal—Capecitabine—esophageal cancer	0.000216	0.00281	CcSEcCtD
Nevirapine—Malaise—Methotrexate—esophageal cancer	0.000216	0.00281	CcSEcCtD
Nevirapine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000215	0.00279	CcSEcCtD
Nevirapine—Nausea—Cisplatin—esophageal cancer	0.000211	0.00275	CcSEcCtD
Nevirapine—Urticaria—Capecitabine—esophageal cancer	0.000208	0.00271	CcSEcCtD
Nevirapine—Abdominal pain—Capecitabine—esophageal cancer	0.000207	0.0027	CcSEcCtD
Nevirapine—Body temperature increased—Capecitabine—esophageal cancer	0.000207	0.0027	CcSEcCtD
Nevirapine—Arthralgia—Methotrexate—esophageal cancer	0.000204	0.00265	CcSEcCtD
Nevirapine—Myalgia—Methotrexate—esophageal cancer	0.000204	0.00265	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000202	0.00263	CcSEcCtD
Nevirapine—Discomfort—Methotrexate—esophageal cancer	0.000201	0.00262	CcSEcCtD
Nevirapine—Anaphylactic shock—Methotrexate—esophageal cancer	0.000195	0.00254	CcSEcCtD
Nevirapine—Hypersensitivity—Capecitabine—esophageal cancer	0.000193	0.00251	CcSEcCtD
Nevirapine—Nervous system disorder—Methotrexate—esophageal cancer	0.000192	0.00249	CcSEcCtD
Nevirapine—Thrombocytopenia—Methotrexate—esophageal cancer	0.000191	0.00249	CcSEcCtD
Nevirapine—Skin disorder—Methotrexate—esophageal cancer	0.00019	0.00247	CcSEcCtD
Nevirapine—Asthenia—Capecitabine—esophageal cancer	0.000188	0.00245	CcSEcCtD
Nevirapine—Anorexia—Methotrexate—esophageal cancer	0.000186	0.00242	CcSEcCtD
Nevirapine—Pruritus—Capecitabine—esophageal cancer	0.000186	0.00241	CcSEcCtD
Nevirapine—Diarrhoea—Capecitabine—esophageal cancer	0.000179	0.00233	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000178	0.00231	CcSEcCtD
Nevirapine—Paraesthesia—Methotrexate—esophageal cancer	0.000175	0.00228	CcSEcCtD
Nevirapine—Somnolence—Methotrexate—esophageal cancer	0.000174	0.00226	CcSEcCtD
Nevirapine—Decreased appetite—Methotrexate—esophageal cancer	0.00017	0.00221	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000169	0.00219	CcSEcCtD
Nevirapine—Fatigue—Methotrexate—esophageal cancer	0.000168	0.00219	CcSEcCtD
Nevirapine—Pain—Methotrexate—esophageal cancer	0.000167	0.00217	CcSEcCtD
Nevirapine—Vomiting—Capecitabine—esophageal cancer	0.000167	0.00217	CcSEcCtD
Nevirapine—Rash—Capecitabine—esophageal cancer	0.000165	0.00215	CcSEcCtD
Nevirapine—Dermatitis—Capecitabine—esophageal cancer	0.000165	0.00215	CcSEcCtD
Nevirapine—Headache—Capecitabine—esophageal cancer	0.000164	0.00214	CcSEcCtD
Nevirapine—Feeling abnormal—Methotrexate—esophageal cancer	0.000161	0.00209	CcSEcCtD
Nevirapine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00016	0.00208	CcSEcCtD
Nevirapine—Nausea—Capecitabine—esophageal cancer	0.000156	0.00203	CcSEcCtD
Nevirapine—Urticaria—Methotrexate—esophageal cancer	0.000155	0.00202	CcSEcCtD
Nevirapine—Body temperature increased—Methotrexate—esophageal cancer	0.000154	0.00201	CcSEcCtD
Nevirapine—Abdominal pain—Methotrexate—esophageal cancer	0.000154	0.00201	CcSEcCtD
Nevirapine—Hypersensitivity—Methotrexate—esophageal cancer	0.000144	0.00187	CcSEcCtD
Nevirapine—Asthenia—Methotrexate—esophageal cancer	0.00014	0.00182	CcSEcCtD
Nevirapine—Pruritus—Methotrexate—esophageal cancer	0.000138	0.0018	CcSEcCtD
Nevirapine—Diarrhoea—Methotrexate—esophageal cancer	0.000134	0.00174	CcSEcCtD
Nevirapine—Vomiting—Methotrexate—esophageal cancer	0.000124	0.00161	CcSEcCtD
Nevirapine—Rash—Methotrexate—esophageal cancer	0.000123	0.0016	CcSEcCtD
Nevirapine—Dermatitis—Methotrexate—esophageal cancer	0.000123	0.0016	CcSEcCtD
Nevirapine—Headache—Methotrexate—esophageal cancer	0.000122	0.00159	CcSEcCtD
Nevirapine—Nausea—Methotrexate—esophageal cancer	0.000116	0.00151	CcSEcCtD
Nevirapine—CYP2A6—Metabolism—CA1—esophageal cancer	6.03e-05	0.000535	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—SLC10A2—esophageal cancer	6.03e-05	0.000535	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—SLC52A3—esophageal cancer	5.72e-05	0.000507	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—BLVRB—esophageal cancer	5.72e-05	0.000507	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—SLC52A3—esophageal cancer	5.59e-05	0.000496	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—BLVRB—esophageal cancer	5.59e-05	0.000496	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—CA2—esophageal cancer	5.51e-05	0.000489	CbGpPWpGaD
Nevirapine—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	5.14e-05	0.000456	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—PLCE1—esophageal cancer	5.12e-05	0.000455	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—ADH7—esophageal cancer	5.12e-05	0.000455	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	5.08e-05	0.000451	CbGpPWpGaD
Nevirapine—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	5.07e-05	0.00045	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—CA1—esophageal cancer	4.86e-05	0.000431	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—SLC10A2—esophageal cancer	4.86e-05	0.000431	CbGpPWpGaD
Nevirapine—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	4.84e-05	0.000429	CbGpPWpGaD
Nevirapine—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	4.77e-05	0.000423	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—CA1—esophageal cancer	4.75e-05	0.000422	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—SLC10A2—esophageal cancer	4.75e-05	0.000422	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—ADH1B—esophageal cancer	4.49e-05	0.000399	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—CA2—esophageal cancer	4.45e-05	0.000395	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	4.43e-05	0.000393	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—CA2—esophageal cancer	4.35e-05	0.000386	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	4.34e-05	0.000385	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—TYMP—esophageal cancer	4.29e-05	0.000381	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—CYP26A1—esophageal cancer	4.18e-05	0.000371	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—ADH7—esophageal cancer	4.13e-05	0.000367	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—PLCE1—esophageal cancer	4.13e-05	0.000367	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—ALOX15—esophageal cancer	4.07e-05	0.000361	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—PLCE1—esophageal cancer	4.04e-05	0.000359	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—ADH7—esophageal cancer	4.04e-05	0.000359	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—SLC52A3—esophageal cancer	3.97e-05	0.000353	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—BLVRB—esophageal cancer	3.97e-05	0.000353	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—SLC52A3—esophageal cancer	3.94e-05	0.00035	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—BLVRB—esophageal cancer	3.94e-05	0.00035	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—TPI1—esophageal cancer	3.88e-05	0.000345	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—GSTO1—esophageal cancer	3.88e-05	0.000345	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	3.79e-05	0.000336	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—ALDOB—esophageal cancer	3.72e-05	0.00033	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—ADH1B—esophageal cancer	3.62e-05	0.000322	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—GAPDH—esophageal cancer	3.58e-05	0.000318	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—CRABP1—esophageal cancer	3.55e-05	0.000315	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—ADH1B—esophageal cancer	3.54e-05	0.000314	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	3.52e-05	0.000313	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—TYMP—esophageal cancer	3.46e-05	0.000307	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—TYMP—esophageal cancer	3.39e-05	0.0003	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CA1—esophageal cancer	3.38e-05	0.0003	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—SLC10A2—esophageal cancer	3.38e-05	0.0003	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—GNG7—esophageal cancer	3.38e-05	0.0003	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—CYP26A1—esophageal cancer	3.37e-05	0.000299	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—BLVRB—esophageal cancer	3.37e-05	0.000299	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—SLC52A3—esophageal cancer	3.37e-05	0.000299	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CA1—esophageal cancer	3.35e-05	0.000297	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—SLC10A2—esophageal cancer	3.35e-05	0.000297	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—CYP26A1—esophageal cancer	3.29e-05	0.000292	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—ALOX15—esophageal cancer	3.28e-05	0.000291	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—ALOX15—esophageal cancer	3.21e-05	0.000285	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—ALDH2—esophageal cancer	3.17e-05	0.000281	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—TPI1—esophageal cancer	3.13e-05	0.000278	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—GSTO1—esophageal cancer	3.13e-05	0.000278	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CA2—esophageal cancer	3.09e-05	0.000274	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CA2—esophageal cancer	3.06e-05	0.000272	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—TPI1—esophageal cancer	3.06e-05	0.000272	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—GSTO1—esophageal cancer	3.06e-05	0.000272	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—GSTT1—esophageal cancer	3.01e-05	0.000267	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	3.01e-05	0.000267	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—ALDOB—esophageal cancer	3e-05	0.000267	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	2.99e-05	0.000266	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—ALDOB—esophageal cancer	2.94e-05	0.000261	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—GAPDH—esophageal cancer	2.89e-05	0.000257	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—PLCE1—esophageal cancer	2.87e-05	0.000255	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—ADH7—esophageal cancer	2.87e-05	0.000255	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—CRABP1—esophageal cancer	2.87e-05	0.000254	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—SLC10A2—esophageal cancer	2.86e-05	0.000254	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CA1—esophageal cancer	2.86e-05	0.000254	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—ADH7—esophageal cancer	2.85e-05	0.000253	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—PLCE1—esophageal cancer	2.85e-05	0.000253	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—GAPDH—esophageal cancer	2.83e-05	0.000251	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—ENO1—esophageal cancer	2.82e-05	0.00025	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—PTGS1—esophageal cancer	2.82e-05	0.00025	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	2.82e-05	0.00025	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—CRABP1—esophageal cancer	2.8e-05	0.000249	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—PSME2—esophageal cancer	2.78e-05	0.000247	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—PSME1—esophageal cancer	2.78e-05	0.000247	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—GNG7—esophageal cancer	2.73e-05	0.000242	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—GNG7—esophageal cancer	2.66e-05	0.000236	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CA2—esophageal cancer	2.62e-05	0.000232	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—SLC52A3—esophageal cancer	2.6e-05	0.000231	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—BLVRB—esophageal cancer	2.6e-05	0.000231	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	2.56e-05	0.000227	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—ALDH2—esophageal cancer	2.55e-05	0.000227	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—ADH1B—esophageal cancer	2.52e-05	0.000224	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—ADH1B—esophageal cancer	2.5e-05	0.000222	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—ALDH2—esophageal cancer	2.5e-05	0.000222	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—PLCE1—esophageal cancer	2.43e-05	0.000216	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—ADH7—esophageal cancer	2.43e-05	0.000216	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—GSTT1—esophageal cancer	2.43e-05	0.000216	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—TYMP—esophageal cancer	2.41e-05	0.000214	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	2.41e-05	0.000213	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—CYP2A6—esophageal cancer	2.4e-05	0.000213	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—CYP1B1—esophageal cancer	2.4e-05	0.000213	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—TYMP—esophageal cancer	2.39e-05	0.000212	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—GSTT1—esophageal cancer	2.37e-05	0.000211	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—CYP2A6—esophageal cancer	2.35e-05	0.000208	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CYP26A1—esophageal cancer	2.34e-05	0.000208	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CYP26A1—esophageal cancer	2.32e-05	0.000206	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—ALOX15—esophageal cancer	2.28e-05	0.000203	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—ENO1—esophageal cancer	2.28e-05	0.000202	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—PTGS1—esophageal cancer	2.28e-05	0.000202	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—ALOX15—esophageal cancer	2.26e-05	0.000201	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—CYP19A1—esophageal cancer	2.26e-05	0.0002	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—PSME1—esophageal cancer	2.24e-05	0.000199	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—PSME2—esophageal cancer	2.24e-05	0.000199	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—PTGS1—esophageal cancer	2.23e-05	0.000197	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—ENO1—esophageal cancer	2.23e-05	0.000197	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CA1—esophageal cancer	2.21e-05	0.000196	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—SLC10A2—esophageal cancer	2.21e-05	0.000196	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—PSME1—esophageal cancer	2.19e-05	0.000195	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—PSME2—esophageal cancer	2.19e-05	0.000195	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—GSTO1—esophageal cancer	2.18e-05	0.000193	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—TPI1—esophageal cancer	2.18e-05	0.000193	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—TPI1—esophageal cancer	2.16e-05	0.000192	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—GSTO1—esophageal cancer	2.16e-05	0.000192	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—ADH1B—esophageal cancer	2.13e-05	0.000189	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—ALDOB—esophageal cancer	2.09e-05	0.000185	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—ALDOB—esophageal cancer	2.07e-05	0.000184	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—HMOX1—esophageal cancer	2.06e-05	0.000183	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—TYMP—esophageal cancer	2.04e-05	0.000181	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CA2—esophageal cancer	2.02e-05	0.000179	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—GAPDH—esophageal cancer	2.01e-05	0.000178	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—GAPDH—esophageal cancer	1.99e-05	0.000177	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CRABP1—esophageal cancer	1.99e-05	0.000177	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CYP26A1—esophageal cancer	1.98e-05	0.000176	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—ABCB1—esophageal cancer	1.98e-05	0.000175	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CRABP1—esophageal cancer	1.97e-05	0.000175	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—CYP1B1—esophageal cancer	1.94e-05	0.000172	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—ALOX15—esophageal cancer	1.93e-05	0.000172	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—GNG7—esophageal cancer	1.89e-05	0.000168	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—CYP1B1—esophageal cancer	1.89e-05	0.000168	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—ADH7—esophageal cancer	1.88e-05	0.000167	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—PLCE1—esophageal cancer	1.88e-05	0.000167	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—GNG7—esophageal cancer	1.88e-05	0.000167	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—GSTO1—esophageal cancer	1.84e-05	0.000164	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—TPI1—esophageal cancer	1.84e-05	0.000164	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—CYP19A1—esophageal cancer	1.82e-05	0.000161	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—CYP19A1—esophageal cancer	1.78e-05	0.000158	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—ALDH2—esophageal cancer	1.78e-05	0.000158	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—ALDOB—esophageal cancer	1.77e-05	0.000157	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—ALDH2—esophageal cancer	1.76e-05	0.000156	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—GAPDH—esophageal cancer	1.7e-05	0.000151	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—GSTT1—esophageal cancer	1.69e-05	0.00015	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CRABP1—esophageal cancer	1.69e-05	0.00015	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—GSTT1—esophageal cancer	1.67e-05	0.000149	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CYP2A6—esophageal cancer	1.67e-05	0.000148	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—HMOX1—esophageal cancer	1.66e-05	0.000147	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CYP2A6—esophageal cancer	1.65e-05	0.000147	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.65e-05	0.000146	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—ADH1B—esophageal cancer	1.65e-05	0.000146	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—HMOX1—esophageal cancer	1.62e-05	0.000144	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—GNG7—esophageal cancer	1.6e-05	0.000142	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—ABCB1—esophageal cancer	1.59e-05	0.000141	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—ENO1—esophageal cancer	1.58e-05	0.00014	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—PTGS1—esophageal cancer	1.58e-05	0.00014	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—TYMP—esophageal cancer	1.57e-05	0.00014	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—PTGS1—esophageal cancer	1.57e-05	0.000139	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—ENO1—esophageal cancer	1.57e-05	0.000139	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—PSME1—esophageal cancer	1.56e-05	0.000138	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—PSME2—esophageal cancer	1.56e-05	0.000138	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—ABCB1—esophageal cancer	1.56e-05	0.000138	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—PSME1—esophageal cancer	1.55e-05	0.000137	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—PSME2—esophageal cancer	1.55e-05	0.000137	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.53e-05	0.000136	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—ALDH2—esophageal cancer	1.5e-05	0.000133	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—ALOX15—esophageal cancer	1.49e-05	0.000132	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—GSTT1—esophageal cancer	1.43e-05	0.000127	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GSTO1—esophageal cancer	1.42e-05	0.000126	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—TPI1—esophageal cancer	1.42e-05	0.000126	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CYP2A6—esophageal cancer	1.41e-05	0.000125	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.41e-05	0.000125	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—ALDOB—esophageal cancer	1.36e-05	0.000121	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.35e-05	0.00012	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CYP1B1—esophageal cancer	1.35e-05	0.000119	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—PTGS1—esophageal cancer	1.34e-05	0.000119	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—ENO1—esophageal cancer	1.34e-05	0.000119	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CYP1B1—esophageal cancer	1.33e-05	0.000118	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—PSME2—esophageal cancer	1.32e-05	0.000117	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—PSME1—esophageal cancer	1.32e-05	0.000117	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—CREBBP—esophageal cancer	1.32e-05	0.000117	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GAPDH—esophageal cancer	1.31e-05	0.000117	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CRABP1—esophageal cancer	1.3e-05	0.000116	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CYP19A1—esophageal cancer	1.26e-05	0.000112	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CYP19A1—esophageal cancer	1.25e-05	0.000111	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GNG7—esophageal cancer	1.24e-05	0.00011	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—NOS3—esophageal cancer	1.18e-05	0.000105	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.16e-05	0.000103	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—HMOX1—esophageal cancer	1.15e-05	0.000102	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.15e-05	0.000102	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—HMOX1—esophageal cancer	1.14e-05	0.000102	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CYP1B1—esophageal cancer	1.14e-05	0.000101	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.12e-05	9.96e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—ABCB1—esophageal cancer	1.11e-05	9.83e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.1e-05	9.8e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—ABCB1—esophageal cancer	1.1e-05	9.75e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.09e-05	9.68e-05	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—PTGS2—esophageal cancer	1.08e-05	9.59e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CYP19A1—esophageal cancer	1.07e-05	9.51e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—CREBBP—esophageal cancer	1.07e-05	9.45e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—CREBBP—esophageal cancer	1.04e-05	9.24e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—ENO1—esophageal cancer	1.03e-05	9.18e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.03e-05	9.18e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—PSME2—esophageal cancer	1.02e-05	9.04e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—PSME1—esophageal cancer	1.02e-05	9.04e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—HMOX1—esophageal cancer	9.78e-06	8.68e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	9.59e-06	8.51e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—NOS3—esophageal cancer	9.54e-06	8.46e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—ABCB1—esophageal cancer	9.39e-06	8.33e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—NOS3—esophageal cancer	9.32e-06	8.27e-05	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—EP300—esophageal cancer	8.99e-06	7.98e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	8.8e-06	7.8e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—PTGS2—esophageal cancer	8.72e-06	7.74e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—PTGS2—esophageal cancer	8.53e-06	7.57e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	8.3e-06	7.37e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	8.27e-06	7.34e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—HMOX1—esophageal cancer	7.55e-06	6.7e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CREBBP—esophageal cancer	7.4e-06	6.57e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CREBBP—esophageal cancer	7.34e-06	6.51e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—EP300—esophageal cancer	7.26e-06	6.44e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—ABCB1—esophageal cancer	7.24e-06	6.43e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	7.1e-06	6.3e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—EP300—esophageal cancer	7.09e-06	6.29e-05	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—PIK3CA—esophageal cancer	6.65e-06	5.9e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—NOS3—esophageal cancer	6.63e-06	5.88e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—NOS3—esophageal cancer	6.57e-06	5.83e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CREBBP—esophageal cancer	6.27e-06	5.57e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—PTGS2—esophageal cancer	6.06e-06	5.38e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—PTGS2—esophageal cancer	6.01e-06	5.33e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—NOS3—esophageal cancer	5.62e-06	4.98e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—PIK3CA—esophageal cancer	5.37e-06	4.76e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—PIK3CA—esophageal cancer	5.25e-06	4.65e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—PTGS2—esophageal cancer	5.14e-06	4.56e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—EP300—esophageal cancer	5.04e-06	4.47e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—EP300—esophageal cancer	5e-06	4.44e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CREBBP—esophageal cancer	4.84e-06	4.3e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—NOS3—esophageal cancer	4.33e-06	3.85e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—EP300—esophageal cancer	4.27e-06	3.79e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—PTGS2—esophageal cancer	3.96e-06	3.52e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—PIK3CA—esophageal cancer	3.73e-06	3.31e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—PIK3CA—esophageal cancer	3.7e-06	3.28e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—EP300—esophageal cancer	3.3e-06	2.93e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—PIK3CA—esophageal cancer	3.16e-06	2.8e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	2.44e-06	2.16e-05	CbGpPWpGaD
